The CDC73 gene (also known as HRPT2) provides instructions for making a protein called parafibromin. This protein is found primarily in the nucleus of cells and is likely involved in regulating gene transcription, which is the first step in protein production. Parafibromin functions as a tumor suppressor, which means it keeps cells from growing and dividing (proliferating) too rapidly or in an uncontrolled way. When parafibromin is found outside the nucleus, it appears to be involved in the organization of the cell's structural framework (the cytoskeleton).
Health Conditions Related to Genetic Changes
Familial isolated hyperparathyroidism
Inherited mutations in the CDC73 gene have been found in some families with familial isolated hyperparathyroidism, a condition characterized by overactivity of the parathyroid glands (primary hyperparathyroidism). These glands release a hormone that helps control the normal balance of calcium in the blood. Primary hyperparathyroidism disrupts this balance, which can lead to high blood calcium levels (hypercalcemia), kidney stones, thinning of the bones (osteoporosis), nausea, vomiting, high blood pressure (hypertension), weakness, and fatigue. Primary hyperparathyroidism is a characteristic feature of hyperparathyroidism-jaw tumor syndrome (described below); however, familial isolated hyperparathyroidism is diagnosed in people with hyperparathyroidism but not the other features of hyperparathyroidism-jaw tumor syndrome.
CDC73 gene mutations that cause familial isolated hyperparathyroidism likely result in decreased activity of the parafibromin protein. Reduced parafibromin activity can cause increased cell proliferation, leading to the formation of tumors involving the parathyroid glands. Parathyroid tumors in people with familial isolated hyperparathyroidism are usually noncancerous (benign). The tumors cause the glands to be overactive, and this overactivity leads to the signs and symptoms of the condition. The mutations associated with familial isolated hyperparathyroidism are thought to have a less severe effect on protein function than those that cause hyperparathyroidism-jaw tumor syndrome. Occasionally, individuals with familial isolated hyperparathyroidism later develop features of hyperparathyroidism-jaw tumor syndrome, although some never do. Familial isolated hyperparathyroidism caused by CDC73 gene mutations may be an early or mild form of hyperparathyroidism-jaw tumor syndrome.More About This Health Condition
Hyperparathyroidism-jaw tumor syndrome
More than 45 inherited mutations in the CDC73 gene have been found to cause hyperparathyroidism-jaw tumor syndrome, which is a condition characterized by a type of benign tumor called a fibroma in the jaw and parathyroid tumors that cause hyperparathyroidism. Hyperparathyroidism disrupts the normal balance of calcium in the blood, which can lead to kidney stones, osteoporosis, nausea, vomiting, hypertension, weakness, and fatigue in people with hyperparathyroidism-jaw tumor syndrome.
Most of the CDC73 gene mutations that cause this condition result in a parafibromin protein that is abnormally short and nonfunctional. Without functional parafibromin, cell proliferation is not properly regulated. Uncontrolled cell division resulting from the loss of parafibromin function can lead to the formation of tumors in the parathyroid glands, jaw, and other tissues in people with hyperparathyroidism-jaw tumor syndrome. Parathyroid tumors, which can be cancerous or noncancerous, interfere with the gland's normal function and lead to primary hyperparathyroidism in people with hyperparathyroidism-jaw tumor syndrome.More About This Health Condition
Mutations in the CDC73 gene are found in up to 70 percent of cases of parathyroid cancer. In approximately one-third of affected individuals with changes in this gene, the mutation is inherited from a parent and is present in all of the body's cells (germline mutation). However, not everyone who inherits a mutation in the CDC73 gene will ultimately develop parathyroid cancer. Other genetic and non-genetic factors also contribute to a person's cancer risk.
In the remaining two-thirds of individuals with CDC73 gene mutations, the condition is associated with a mutation that occurs in parathyroid cells during their lifetime (somatic mutation). In individuals with either a germline or somatic CDC73 gene mutation, a second mutation in the other copy of the CDC73 gene must occur for parathyroid cancer to develop. Parathyroid cells with two altered copies of the CDC73 gene produce no functional parafibromin. As a result, cells grow and divide unchecked, which can lead to parathyroid cancer.
A significantly increased risk of parathyroid cancer is a feature of hyperparathyroidism-jaw tumor syndrome and familial isolated hyperparathyroidism (both described above). Parathyroid cancer occurs in 15 percent of individuals with hyperparathyroidism-jaw tumor syndrome and in 1 percent of individuals with familial isolated hyperparathyroidism. It is unclear why some CDC73 gene mutations cause isolated parathyroid cancer, others cause noncancerous tumors in the parathyroid glands and jaw, and still others cause only hyperparathyroidism.More About This Health Condition
Other Names for This Gene
- cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)
- cell division cycle protein 73 homolog
- hyperparathyroidism 2 protein
Additional Information & Resources
Tests Listed in the Genetic Testing Registry
Scientific Articles on PubMed
Catalog of Genes and Diseases from OMIM
- Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceicao Pereira M, Davie MW, Dudley N, Leite V, Sadler GP, Seller A, Thakker RV. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf). 2006 Mar;64(3):299-306. doi: 10.1111/j.1365-2265.2006.02460.x. Citation on PubMed
- Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest. 2016 Jun;39(6):595-606. doi: 10.1007/s40618-016-0447-3. Epub 2016 Mar 21. Citation on PubMed
- Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2009 Jan 15;115(2):334-44. doi: 10.1002/cncr.24037. Citation on PubMed
- Masi G, Barzon L, Iacobone M, Viel G, Porzionato A, Macchi V, De Caro R, Favia G, Palu G. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer. 2008 Dec;15(4):1115-26. doi: 10.1677/ERC-08-0066. Epub 2008 Aug 28. Citation on PubMed
- Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010 Mar;31(3):295-307. doi: 10.1002/humu.21188. Citation on PubMed
- Newey PJ, Bowl MR, Thakker RV. Parafibromin--functional insights. J Intern Med. 2009 Jul;266(1):84-98. doi: 10.1111/j.1365-2796.2009.02107.x. Citation on PubMed
- Serrano-Gonzalez M, Shay S, Austin J, Maceri DR, Pitukcheewanont P. A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature. J Pediatr Endocrinol Metab. 2016 Sep 1;29(9):1005-12. doi: 10.1515/jpem-2016-0109. Citation on PubMed
- Villablanca A, Calender A, Forsberg L, Hoog A, Cheng JD, Petillo D, Bauters C, Kahnoski K, Ebeling T, Salmela P, Richardson AL, Delbridge L, Meyrier A, Proye C, Carpten JD, Teh BT, Robinson BG, Larsson C. Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet. 2004 Mar;41(3):e32. doi: 10.1136/jmg.2003.012369. No abstract available. Citation on PubMed or Free article on PubMed Central
- Wang PF, Tan MH, Zhang C, Morreau H, Teh BT. HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome. Horm Metab Res. 2005 Jun;37(6):380-3. doi: 10.1055/s-2005-870150. Citation on PubMed
- Westin G. Molecular genetics and epigenetics of nonfamilial (sporadic) parathyroid tumours. J Intern Med. 2016 Dec;280(6):551-558. doi: 10.1111/joim.12458. Epub 2016 Apr 12. Citation on PubMed
The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.